Clarity Pharmaceuticals Initiates Theranostic Prostate Cancer Trial in the US

Clarity Pharmaceuticals (ASX: CU6) has initiated its Phase I/II trial for theranostic prostate cancer treatment in the US. The clinical trial, named COMBAT, seeks to evaluate the safety and effectiveness of 67Cu-SAR-Bombesin in patients diagnosed with metastatic castrate-resistant prostate cancer (mCRPC) who are not eligible for treatment with 177Lu PSMA-617.The trial will involve up to 38 participants and will include dose escalation and cohort expansion.

SAR-Bombesin is a targeted radiopharmaceutical that utilizes Clarity's proprietary SAR technology to securely hold copper isotopes. The radiopharmaceutical targets the gastrin-releasing peptide receptor (GRPr), which is present in multiple cancer types such as prostate, breast, and ovarian cancers. Since a significant proportion of prostate cancers express GRPr, SAR-Bombesin offers a potential treatment option for patients with limited therapeutic choices. Clarity aims to build on the promising data from preclinical and diagnostic trials to confirm the safety and effectiveness of SAR-Bombesin in the theranostic trial.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com